Argos Therapeutics to Participate in 2016 EORTC-AACR-NCI Symposium
November 29 2016 - 8:00AM
Argos Therapeutics Inc. (Nasdaq:ARGS) (“Argos”), an immuno-oncology
company focused on the development and commercialization of
individualized immunotherapies based on the Arcelis® technology
platform, today announced that the company will be presenting at
the EORTC-AACR-NCI Symposium being held November 29-December 1 at
the Internationales Congress Center München in Munich, Germany.
Irina Tcherepanova, Ph.D., senior director of
research and development for Argos, will give a poster presentation
entitled “Development of an RNA loaded Dendritic Cell (DC)
immunotherapy starting from tissue obtained via needle
biopsy”. The poster will be exhibited in the meeting
exhibition hall throughout the day on November 30th.
The EORTC-NCI-AACR Symposium is hosted by the
European Organisation for Research and Treatment of Cancer (EORTC),
the National Cancer Institute (NCI), and the American Association
of Cancer Research (AACR), and brings together academics,
scientists, and industry representatives from around the world to
review the latest innovations in drug development, target selection
and the impact of new discoveries in molecular biology.
For more information visit
http://www.ecco-org.eu/ENA2016.
About the Arcelis® Technology
PlatformArcelis® is a precision
immunotherapy technology that captures both mutated and variant
antigens that are specific to each patient’s individual disease. It
is designed to overcome immunosuppression by producing a
specifically targeted, durable memory T-cell response without
adjuvants that may be associated with toxicity. The technology is
potentially applicable to the treatment of a wide range of
different cancers and infectious diseases and is designed to
overcome many of the manufacturing and commercialization challenges
that have impeded other personalized immunotherapies. The
Arcelis® process uses only a small disease sample
or biopsy as the source of disease-specific antigens and the
patient’s own dendritic cells, which are optimized from cells
collected by a leukapheresis procedure. The proprietary process
uses RNA isolated from the patient's disease sample to program
dendritic cells to target disease-specific antigens. These
activated, antigen-loaded dendritic cells are then formulated with
the patient’s plasma and administered via intradermal injection as
an individualized immunotherapy.
About Argos TherapeuticsArgos
Therapeutics is an immuno-oncology company focused on the
development and commercialization of individualized immunotherapies
for the treatment of cancer and infectious diseases using its
Arcelis® technology platform. Argos' most advanced
product candidate, AGS-003, is being evaluated in
the pivotal ADAPT Phase 3 clinical trial for the
treatment of mRCC. In addition, AGS-003 is being
studied in Phase 2 investigator-initiated clinical
trials as neoadjuvant therapy for RCC and for the treatment of
NSCLC. Argos is also developing a separate
Arcelis®-based product candidate,
AGS-004, for the treatment of human
immunodeficiency virus (HIV), which is currently being evaluated in
an investigator-initiated clinical trial aimed at HIV eradication
in adult patients.
Forward Looking StatementsAny
statements in this press release about Argos’ future expectations,
plans and prospects, including statements about the expected and
potential future closings of the private placement, Argos’
financial prospects, anticipated use of proceeds, future operations
and sufficiency of funds for future operations, clinical
development of Argos’ product candidates, expectations regarding
future clinical trials and future expectations and plans and
prospects for Argos and other statements containing the words
"believes," "anticipates," "estimates," "expects," "intends,"
"plans," "predicts," "projects," "targets," “may,” "potential,"
"will," "would," "could," "should," "continue," and similar
expressions, constitute forward-looking statements within the
meaning of The Private Securities Litigation Reform Act of
1995. Actual results may differ materially from those
indicated by such forward-looking statements as a result of various
important factors, including whether Argos' cash resources will be
sufficient to fund its continuing operations for the periods
anticipated; whether results obtained in clinical trials will be
indicative of results obtained in future clinical trials; whether
Argos' product candidates will advance through the clinical trial
process on a timely basis; whether the results of such trials will
warrant submission for approval from the United States Food and
Drug Administration or equivalent foreign regulatory
agencies; whether Argos' product candidates will receive
approval from regulatory agencies on a timely basis or at all;
whether, if product candidates obtain approval, they will be
successfully distributed and marketed; and other factors discussed
in the "Risk Factors" section of Argos’ Form 10-Q for the quarter
ended September 30, 2016, which is on file with the SEC, and in
other filings Argos makes with the SEC from time to time. In
addition, the forward-looking statements included in this press
release represent Argos’ views as of the date hereof. Argos
anticipates that subsequent events and developments will cause
Argos’ views to change. However, while Argos may elect to update
these forward-looking statements at some point in the future, Argos
specifically disclaims any obligation to do so. These
forward-looking statements should not be relied upon as
representing Argos’ views as of any date subsequent to the date
hereof.
Media contact:
Adam Daley
Berry & Company Public Relations
212-253-8881
adaley@berrypr.com
Investor contact:
John Menditto
Argos Therapeutics, Inc.
919-908-0687
jmenditto@argostherapeutics.com